-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Jjwh3F6F1uKU9QnuPDAbsmDlMHru50tIxAhgPjw/2iuqy2PPQOYUFO6X3Kgmy4lU
 3y2PEEJwWz7ieYoFfR1IMg==

<SEC-DOCUMENT>/in/edgar/work/20000720/0000950130-00-003955/0000950130-00-003955.txt : 20000920
<SEC-HEADER>0000950130-00-003955.hdr.sgml : 20000920
ACCESSION NUMBER:		0000950130-00-003955
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20000720
ITEM INFORMATION:		
FILED AS OF DATE:		20000720

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BECTON DICKINSON & CO
		CENTRAL INDEX KEY:			0000010795
		STANDARD INDUSTRIAL CLASSIFICATION:	 [3841
]		IRS NUMBER:				220760120
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0930
</COMPANY-DATA>

		FILING VALUES:
			FORM TYPE:		8-K
			SEC ACT:		
			SEC FILE NUMBER:	001-04802
			FILM NUMBER:		676038
</FILING-VALUES>

			BUSINESS ADDRESS:	
				STREET 1:		ONE BECTON DR
				CITY:			FRANKLIN LAKES
				STATE:			NJ
				ZIP:			07417-1880
				BUSINESS PHONE:		2018476800
</BUSINESS-ADDRESS>

				MAIL ADDRESS:	
					STREET 1:		ONE BECTON DR
					CITY:			FRANKLIN LAKE
					STATE:			NJ
					ZIP:			07417
</MAIL-ADDRESS>
</FILER>
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>0001.txt
<DESCRIPTION>FORM 8-K
<TEXT>

<PAGE>


                      SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549


                                   FORM 8-K

                                CURRENT REPORT


                    Pursuant to Section 13 or 15(d) of the
                        Securities Exchange Act of 1934


Date of Report (Date of earliest event reported)  July 20, 2000
                                                  -------------


                         BECTON, DICKINSON AND COMPANY
- --------------------------------------------------------------------------------
            (Exact name of registrant as specified in its charter)

           New Jersey                001-4802                   22-0760120
- --------------------------------------------------------------------------------
    (State or other juris-         (Commission             (IRS Employer Iden-
   diction of incorporation)       File Number)            tification Number)


   1 Becton Drive, Franklin Lakes, New Jersey                   07417-1880
- --------------------------------------------------------------------------------
    (Address of principal executive offices)                    (Zip Code)


Registrant's telephone number, including area code          (201) 847-6800
                                                            --------------

                                      N/A
- --------------------------------------------------------------------------------
        (Former name or former addresses if changed since last report.)


<PAGE>

Item 5.      OTHER EVENTS
             ------------

             On July 20, 2000 the Registrant announced in a press release its
             results for the third quarter ended June 30, 2000. Attached hereto
             as Exhibit 99, which is incorporated herein by reference, is a copy
             of such press release.


<PAGE>


                                  SIGNATURES


        Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                           BECTON, DICKINSON AND COMPANY
                                                  (Registrant)



                                           By: /s/ Bridget M. Healy
                                               ---------------------
                                                   Bridget M. Healy
                                                    Vice President


Date: July 20, 2000

                                     - 2 -
<PAGE>

                              INDEX TO EXHIBITS
                              -----------------

   Exhibit
   Number              Description of Exhibits
   ------              -----------------------

    99                 Press Release issued on July 20, 2000


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>0002.txt
<DESCRIPTION>PRESS RELEASE DATED JULY 20, 2000
<TEXT>

<PAGE>

                                                                      Exhibit 99


Refer to:   Ronald Jasper
            Director, Investor Relations
            (201) 847-7160


                 BD ANNOUNCES RESULTS FOR THIRD FISCAL QUARTER

              SAFETY AND BIOSCIENCES SALES ADD TO TOP LINE GROWTH

     Franklin Lakes, NJ (July 20, 2000) - BD (Becton, Dickinson and Company)
(NYSE:BDX) announced today diluted earnings per share of $.43 for its third
fiscal quarter which ended June 30, 2000.  Earnings per share included a gain on
the sale of an equity investment offset, in part, by charges related to the
acquisition of in-process research and development and the write-down of an
asset held for sale.  The net favorable impact of these items was $.03.  Foreign
currency translation reduced the quarter's earnings by an estimated $.03
primarily as a result of the weak Euro versus a year ago.  Excluding the gain
and charges noted above, earnings per share for the third quarter were $.40, or
$.43 on a foreign currency neutral basis ("FX-neutral").  Third quarter 1999
earnings per share were $.12, or $.38 after excluding the effects of special and
other charges, as described in the Company's 1999 Annual Report on Form 10K.

     Reported revenues for the quarter were $914 million, an increase of 5
percent over last year, or 8 percent on an FX-neutral basis.
<PAGE>

                                      -2-


     Edward J. Ludwig, President and Chief Executive Officer, said: "Top line
growth was led by revenues from our advanced protection (safety-engineered)
devices and sales contributions from recent Biosciences segment acquisitions.
Customer conversions to advanced protection devices continue to accelerate based
on recently updated Federal OSHA regulations and legislation enacted in a
growing number of key states.  In Biosciences, the recent acquisition of
Clontech Laboratories, Inc. is contributing significantly to the growth of our
flow cytometry sales.  We remain committed to building these franchises and
delivering results consistent with our expectations."

     By business segment, Medical Systems segment revenues grew 7 percent for
the quarter on an FX-neutral basis to $512 million, led by sales of advanced
protection devices and pre-fillable syringes which continue to show strong
growth.  Preanalytical Solutions segment revenues grew 3 percent for the quarter
on an FX-neutral basis to $133 million.  Shifts in inventory levels by a key
distributor during the quarter resulted in lower reported Preanalytical
Solutions sales.  End-user demand for Preanalytical Solutions products remains
strong, led by sales of advanced protection devices.   Preanalytical Solution
sales are expected to return, on an FX-neutral basis, to approximately 10
percent in the fourth quarter.  Biosciences segment revenues of $269 million
grew 12 percent for the quarter on an FX-neutral basis, which reflects sales
from the Clontech acquisition in late 1999.
<PAGE>

                                      -3-

     By geographic area, revenues inside the United States were $481 million,
7 percent higher than a year earlier, while revenues outside the United States
grew 8 percent, FX-neutral, to $433 million. Strong growth was experienced in
Latin America and Asia.

                               Nine-Month Results
                               ------------------

     For the nine-month period ended June 30, 2000, revenues were $2.698
billion, a 7 percent increase over $2.516 billion a year ago. Excluding the
unfavorable foreign currency translation that reduced revenues by an estimated
$53 million for the nine-month period, revenues grew 9 percent over the prior
year. Medical Systems revenues for the nine-month period were $1.464 billion,
Preanalytical Solutions revenues totaled $404 million, and Biosciences revenues
were $830 million.



                                    *   *  *


        This press release may contain certain forward-looking statements (as
defined under Federal securities laws) regarding the Company's performance,
including future revenues, products and income, or events or developments that
the Company expects to occur or anticipates occurring in the future.  All such
statements are based upon current expectations of the Company and involve a
number of business risks and uncertainties. Actual results could vary materially
from anticipated results described in any forward-looking statement.  Factors
that could cause actual results to vary materially from any forward-looking
statement include, but are not limited to, competitive factors, changes in
regional, national or foreign economic conditions, changes in interest or
foreign currency exchange rates, delays in product introductions, and changes in
health care or other governmental regulation, as well as other factors discussed
herein and in the Company's filings with the Securities and Exchange Commission.

                  -  Selected Financial Schedules follow   -


                                    # # # #
<PAGE>

                                     -4-


BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
<TABLE>
<CAPTION>

                                                           Three Months Ended June 30,
                                                      2000                    1999        % Change
- ------------------------------------------------------------------------------------------------------
<S>                                          <C>               <C>                    <C>
REVENUES                                     $       914,140   $      873,002            4.7

Cost of products sold                                453,838          461,323           (1.6)
Selling and administrative                           248,773          231,924            7.3
Research and development                              60,202           50,694           18.8
Special charges                                            -           75,553             NM
- ---------------------------------------------------------------------------------------------
TOTAL OPERATING COSTS
     AND EXPENSES                                    762,813          819,494           (6.9)
- ---------------------------------------------------------------------------------------------

OPERATING INCOME                                     151,327           53,508          NM

Interest expense, net                                (17,564)         (16,877)           4.1
Other income (expense), net                           27,745           (1,267)         NM
- ---------------------------------------------------------------------------------------------

INCOME BEFORE
     INCOME TAXES                                    161,508           35,364          NM

Income tax provision                                  47,090            2,240          NM
- ---------------------------------------------------------------------------------------------

NET INCOME                                   $       114,418   $       33,124          NM
- ---------------------------------------------------------------------------------------------

EARNINGS PER SHARE

     Basic                                   $          0.45   $         0.13          NM
     Diluted                                 $          0.43   $         0.12          NM
- ---------------------------------------------------------------------------------------------

AVERAGE SHARES OUTSTANDING

     Basic                                           252,904          250,075
     Diluted                                         263,659          265,072
- ---------------------------------------------------------------------------------------------
</TABLE>
NM - Not Meaningful

<PAGE>

                                     -5-


BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)
<TABLE>
<CAPTION>

                                                            Nine Months Ended June 30,
                                                      2000                    1999        % Change
- ------------------------------------------------------------------------------------------------------
<S>                                          <C>               <C>                        <C>
REVENUES                                     $     2,698,436   $     2,515,932            7.3

Cost of products sold                              1,377,776         1,276,293            8.0
Selling and administrative                           726,674           688,044            5.6
Research and development                             171,120           167,255            2.3
Special charges                                            -            75,553             NM
- ----------------------------------------------------------------------------------------------
TOTAL OPERATING COSTS
     AND EXPENSES                                  2,275,570         2,207,145            3.1
- ----------------------------------------------------------------------------------------------

OPERATING INCOME                                     422,866           308,787           36.9

Interest expense, net                                (60,320)          (53,506)          12.7
Other income, net                                     65,818             1,218          NM
- ----------------------------------------------------------------------------------------------

INCOME BEFORE
        INCOME TAXES                                 428,364           256,499           67.0

Income tax provision                                 119,481            57,103          NM
- ----------------------------------------------------------------------------------------------

NET INCOME                                   $       308,883   $       199,396           54.9
- ----------------------------------------------------------------------------------------------

EARNINGS PER SHARE

     Basic                                   $          1.22   $          0.79           54.4
     Diluted                                 $          1.17   $          0.75           56.0
- ----------------------------------------------------------------------------------------------

AVERAGE SHARES OUTSTANDING

     Basic                                           252,093           249,213
     Diluted                                         263,192           265,335
- ----------------------------------------------------------------------------------------------
</TABLE>
NM - Not Meaningful

<PAGE>

                                     -6-

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>
                                                           Three Months Ended June 30,
                                                      2000                    1999        % Change
                                             ---------------------------------------------------------
<S>                                          <C>               <C>                        <C>
MEDICAL SYSTEMS
   United States                             $       249,407   $       237,646            4.9
   International                                     262,775           257,489            2.1
- ----------------------------------------------------------------------------------------------
TOTAL                                        $       512,182   $       495,135            3.4
- ----------------------------------------------------------------------------------------------

BIOSCIENCES
   United States                             $       158,932   $       136,292           16.6
   International                                     110,408           108,970            1.3
- ----------------------------------------------------------------------------------------------
TOTAL                                        $       269,340   $       245,262            9.8
- ----------------------------------------------------------------------------------------------

PREANALYTICAL SOLUTIONS
   United States                             $        73,062   $        75,678           (3.5)
   International                                      59,556            56,927            4.6
- ----------------------------------------------------------------------------------------------
TOTAL                                        $       132,618   $       132,605              -
- ----------------------------------------------------------------------------------------------

TOTAL REVENUES
   United States                             $       481,401   $       449,616            7.1
   International                                     432,739           423,386            2.2
- ----------------------------------------------------------------------------------------------
TOTAL                                        $       914,140   $       873,002            4.7
- ----------------------------------------------------------------------------------------------

                                                        Nine Months ended June 30,
                                                  2000                1999         % Change
                                             -------------------------------------------------
MEDICAL SYSTEMS
   United States                             $       688,032   $       656,712            4.8
   International                                     776,085           747,366            3.8
- ----------------------------------------------------------------------------------------------
TOTAL                                        $     1,464,117   $     1,404,078            4.3
- ----------------------------------------------------------------------------------------------

BIOSCIENCES
   United States                             $       481,028   $       401,873           19.7
   International                                     349,045           328,993            6.1
- ----------------------------------------------------------------------------------------------
TOTAL                                        $       830,073   $       730,866           13.6
- ----------------------------------------------------------------------------------------------

PREANALYTICAL SOLUTIONS
   United States                             $       220,539   $       208,382            5.8
   International                                     183,707           172,606            6.4
- ----------------------------------------------------------------------------------------------
TOTAL                                        $       404,246   $       380,988            6.1
- ----------------------------------------------------------------------------------------------

TOTAL REVENUES
   United States                             $     1,389,599   $     1,266,967            9.7
   International                                   1,308,837         1,248,965            4.8
- ----------------------------------------------------------------------------------------------
TOTAL                                        $     2,698,436   $     2,515,932            7.3
- ----------------------------------------------------------------------------------------------
</TABLE>

<PAGE>

                                     -7-


BECTON DICKINSON AND COMPANY
SELECTED FINANCIAL INFORMATION
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

CONDENSED                                           June 30,           September 30,
BALANCE SHEETS                                        2000                 1999
- ---------------------------------------------------------------------------------------
<S>                                          <C>               <C>
Cash & equivalents                           $        76,940   $       59,932
Trade receivables, net                               753,227          812,544
Inventories                                          706,565          642,533
Other                                                171,294          168,716
- ------------------------------------------------------------------------------

TOTAL CURRENT ASSETS                               1,708,026        1,683,725
- ------------------------------------------------------------------------------

Property, plant & equipment, net                   1,538,884        1,431,149
Other                                              1,313,897        1,322,084
- ------------------------------------------------------------------------------

TOTAL ASSETS                                 $     4,560,807   $    4,436,958
- ------------------------------------------------------------------------------

Current Liabilities                          $     1,440,418   $    1,329,322
Long-term Liabilities                              1,165,024        1,338,948
Equity                                             1,955,365        1,768,688
- ------------------------------------------------------------------------------

TOTAL LIABILITIES & EQUITY                   $     4,560,807   $    4,436,958
- ------------------------------------------------------------------------------

                                                      Nine Months Ended
SELECTED CASH                                              June 30,
FLOW INFORMATION                                  2000               1999
- ------------------------------------------------------------------------------

Depreciation & amortization                  $       214,755   $      191,250

Cash flow from operating
activities                                           437,095          299,522

Capital expenditures                                (271,296)        (212,098)

Acquisitions of businesses                           (21,047)        (153,247)

Cash flow from investing
activities                                          (285,822)        (471,786)

Cash flow from financing
activities                                          (134,265)         155,997

Net Change in Cash &
Equivalents                                           17,008          (16,267)
- ------------------------------------------------------------------------------
</TABLE>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
